Moving from Semaglutide to Tirzepatide: What Actually Changes

Step 1: Why patients consider making the switch

Most people who ask about going from semaglutide to tirzepatide have either plateaued on their current dose or have seen emerging evidence and want to understand whether a different medicine could do more. That curiosity is reasonable. The two drugs work differently at a receptor level: semaglutide acts on GLP-1 receptors only, while tirzepatide activates both GIP and GLP-1 receptors simultaneously. In the SURMOUNT-5 head-to-head trial, published in the New England Journal of Medicine in 2025, tirzepatide produced a greater average reduction in body weight than semaglutide 2.4mg over 72 weeks in adults with obesity and no diabetes. That result matters, but it describes averages across a trial population, individual responses vary, and tolerability also differs person to person.

Some patients move the other direction too. Those who do well on semaglutide but find tirzepatide's side-effect profile harder to manage sometimes ask about moving back from Mounjaro to Wegovy, which is equally a clinical conversation rather than a self-managed swap. Neither direction is automatically better. The question is which medicine suits your biology, your history and your goals.

It is also worth being clear about one boundary: Ozempic is semaglutide too, but it is licensed for type 2 diabetes, not weight management. A patient considering a move involving Ozempic is in a different clinical conversation entirely. This page focuses on the licensed weight-loss medicines on both sides.

Step 2: What a prescriber checks before approving the change

Switching is not something a patient can self-initiate by ordering a different pen. At nume, transfer patients and those requesting a dose or medicine change are asked to provide evidence of their current treatment, the dose they are on, how long they have been there, and how they have been responding. A prescriber then reviews the full picture: current BMI, weight trend, any side effects experienced on semaglutide, and whether the eligibility criteria for tirzepatide are met.

The licensed criteria for tirzepatide (Mounjaro) in the UK, as set out in its Summary of Product Characteristics and summarised by the NHS medicines page for tirzepatide, cover adults with a BMI of 30 or above, or 27 and above with at least one weight-related condition such as high blood pressure, raised cholesterol, prediabetes or obstructive sleep apnoea. Those criteria apply whether someone is starting fresh or switching from another medicine. Lower BMI thresholds apply for some ethnic backgrounds under UK guidance.

If you have been on semaglutide for a while, your prescriber will also consider what dose you are currently taking and what the equivalent starting point for tirzepatide should be. Tirzepatide begins at 2.5mg (that first pen's job is adjustment, giving your system time to settle before the dose moves up) so even experienced patients restart the titration ladder. Our clinical team reviews these decisions individually; there is no automated crossover table that replaces that judgement.

Step 3: What changes when you make the switch, a factual comparison

The table below sets out the key differences between the two licensed weight-loss injections, covering the points that matter most to someone deciding between or switching between them.

Both medicines share a broadly similar side-effect profile: nausea, changes in bowel habits, indigestion, fatigue and injection-site reactions are the most commonly reported, generally most noticeable when starting or stepping up. For a fuller breakdown of how the two medicines compare beyond just trial results, the Wegovy vs Mounjaro comparison on this site covers the clinical picture in more depth. You can also read about how the two options stack up on cost and access separately.

One practical note on timing: if you are planning a switch and you order before 12pm on a Monday, your new treatment could reach you the next morning, useful to know if your current pen is running low at the end of a month. Holidays and bank holidays affect DPD delivery windows, so factor that in if you are mid-titration.

Step 4: Making the decision, and what happens next

There is no universal answer to whether moving from semaglutide to tirzepatide is the right step. The SURMOUNT-5 trial data suggest tirzepatide produces greater average weight loss at its highest dose, and NICE's appraisal of tirzepatide (TA1026) notes that indirect comparisons also favour tirzepatide, though the committee acknowledged the evidence base is still developing. What trial averages cannot tell you is how your body will respond, whether you will tolerate the titration well, or whether tirzepatide's dual mechanism produces the same results for you personally.

If you are weighing up semaglutide or tirzepatide from the start, or you want to understand what a move in either direction involves before committing, it helps to read through the specifics carefully. Patients sometimes explore what changing from semaglutide to tirzepatide involves clinically, or look at the practical steps of going from semaglutide to tirzepatide before starting the consultation process. Both are worth reading alongside this page.

Which of these medicines suits you is a clinical decision our prescribers make with you, not something that can be resolved by a comparison table alone. If you are ready to have that conversation, check your eligibility and start your free consultation.